Literature DB >> 11927364

Chronic central infusion of orexin-A increases arterial pressure in rats.

Yingzi Lin1, Kiyoshi Matsumura, Takuya Tsuchihashi, Isao Abe, Mitsuo Iida.   

Abstract

We determined the cardiovascular responses as well as food and water intakes to chronic intracerebroventricular administration of orexin-A and orexin-B for 14 days in conscious rats. Chronic intracerebroventricular infusion of orexin-A (50 pmol/h) elicited a significant increase in systolic blood pressure on the third day (+15.6 +/- 2.9 mm Hg), and during the continuous intracerebroventricular infusion of orexin-A the blood pressure returned to the baseline levels at day 14. In contrast, chronic intracerebroventricular infusion of orexin-B (50 pmol/h) failed to change systolic blood pressure during the 14 days of experimental periods. Chronic intracerebroventricular infusions of neither orexin-A nor orexin-B changed urinary catecholamine excretions, food and water intakes, and urine volumes at 7 and 14 days of infusion periods. Mean arterial pressure directly measured at 14 days did not differ among the groups of orexin-A, orexin-B, and artificial cerebrospinal fluid treatments. Both intravenous injections of pentolinium (5 mg/kg), a ganglion blocking agent, and CV-11974 (0.05 mg/kg), an AT(1) receptor antagonist, decreased arterial pressure; however, these responses were not different among the groups. These results suggest that central orexin-A participates in the short-term regulation of blood pressure; however, the contributions of central orexins to the long-term regulations of blood pressure, sympathetic nervous system, and appetite may be little.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11927364     DOI: 10.1016/s0361-9230(01)00756-0

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  5 in total

Review 1.  Implicating the potential role of orexin in hypertension.

Authors:  Monika Rani; Raghuvansh Kumar; Pawan Krishan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-05-16       Impact factor: 3.000

Review 2.  Respiration and autonomic regulation and orexin.

Authors:  Eugene Nattie; Aihua Li
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

3.  Cerebrospinal fluid hypocretin (orexin) levels are elevated by play but are not raised by exercise and its associated heart rate, blood pressure, respiration or body temperature changes.

Authors:  M-F Wu; R Nienhuis; N Maidment; H A Lam; J M Siegel
Journal:  Arch Ital Biol       Date:  2011-11-07       Impact factor: 1.000

Review 4.  Role of Orexin-A in Hypertension and Obesity.

Authors:  Roberta Imperatore; Letizia Palomba; Luigia Cristino
Journal:  Curr Hypertens Rep       Date:  2017-04       Impact factor: 5.369

Review 5.  OX1 and OX2 orexin/hypocretin receptor pharmacogenetics.

Authors:  Miles D Thompson; Henri Xhaard; Takeshi Sakurai; Innocenzo Rainero; Jyrki P Kukkonen
Journal:  Front Neurosci       Date:  2014-05-06       Impact factor: 4.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.